FDA-cleared profile

QOCA® image Smart RT Contouring System

Quanta Computer Inc. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: QOCA image Smart RT Contouring System automatically contours DICOM CT imaging data using deep-learning algorithms. Generated contours may be used as input to external-beam radiation-therapy planning and are output as RTSTRUCT objects for radiation-oncology departments.

Clinical role
Radiotherapy contouring or planning support before qualified review, editing, independent checks, and approval.
Images and patients
Radiotherapy Planning Imaging · Adult patient anatomy represented in CT images and radiation-treatment structures
Key limitation
Keep in mind: The FDA indication limits valid input to adult-patient DICOM images, states that the software does not automatically detect or contour lesions, and requires appropriate treatment-planning or interactive-contouring software to review, edit, and accept the contours.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: QOCA image Smart RT Contouring System automatically contours DICOM CT imaging data using deep-learning algorithms. Generated contours may be used as input to external-beam radiation-therapy planning and are output as RTSTRUCT objects for radiation-oncology departments.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Adult patient anatomy represented in CT images and radiation-treatment structures Input: Supported CT or MR images, structures, patient identity, treatment-planning data, and user selections.
  • Who uses it?Intended users: Qualified radiation oncologists, medical physicists, dosimetrists, radiation therapists, and trained planning staff.
  • What does the software produce?Output: Contours, RTSTRUCT objects, plans, dose or evaluation results, or review information requiring qualified acceptance.
  • What is its most important limitation?Key limitation: The FDA indication limits valid input to adult-patient DICOM images, states that the software does not automatically detect or contour lesions, and requires appropriate treatment-planning or interactive-contouring software to review, edit, and accept the contours.

Clinical takeaway. Clinical role: QOCA image Smart RT Contouring System automatically contours DICOM CT imaging data using deep-learning algorithms. Generated contours may be used as input to external-beam radiation-therapy planning and are output as RTSTRUCT objects for radiation-oncology departments.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a retrospective standalone performance study on 220 CT cases (110 head and neck, 110 pelvis; each site 50 cases from Taiwan and 60 from the United States public dataset TCIA), independent of the data used in nonclinical tests, with ground truth following consensus contouring guidelines. The subject device achieved a median DSC > 0.80; organs not meeting predefined acceptance criteria were excluded from the intended use. No clinical test was conducted. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
QOCA image Smart RT Contouring System automatically contours DICOM CT imaging data using deep-learning algorithms. Generated contours may be used as input to external-beam radiation-therapy planning and are output as RTSTRUCT objects for radiation-oncology departments.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Radiotherapy contouring or planning support before qualified review, editing, independent checks, and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CT or MR images, structures, patient identity, treatment-planning data, and user selections.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Contours, RTSTRUCT objects, plans, dose or evaluation results, or review information requiring qualified acceptance.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-oncology departments using compatible imaging, contouring, treatment-planning, and review systems.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiation oncologists, medical physicists, dosimetrists, radiation therapists, and trained planning staff.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA indication limits valid input to adult-patient DICOM images, states that the software does not automatically detect or contour lesions, and requires appropriate treatment-planning or interactive-contouring software to review, edit, and accept the contours.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports a retrospective standalone performance study on 220 CT cases (110 head and neck, 110 pelvis; each site 50 cases from Taiwan and 60 from the United States public dataset TCIA), independent of the data used in nonclinical tests, with ground truth following consensus contouring guidelines. The subject device achieved a median DSC > 0.80; organs not meeting predefined acceptance criteria were excluded from the intended use. No clinical test was conducted. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The standalone performance of the subject device has been validated in a retrospective performance study on CT data previously acquired for RT treatment planning." … "Data collection included 110 head and neck CT images and 110 pelvis CT images, with each anatomical site contributing 50 cases from Taiwan and 60 cases from the United States public dataset, TCIA.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports a retrospective standalone performance study on 220 CT cases (110 head and neck, 110 pelvis; each site 50 cases from Taiwan and 60 from the United States public dataset TCIA), independent of the data used in nonclinical tests, with ground truth following consensus contouring guidelines. The subject device achieved a median DSC > 0.80; organs not meeting predefined acceptance criteria were excluded from the intended use. No clinical test was conducted. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The standalone performance of the subject device has been validated in a retrospective performance study on CT data previously acquired for RT treatment planning." … "Data collection included 110 head and neck CT images and 110 pelvis CT images, with each anatomical site contributing 50 cases from Taiwan and 60 cases from the United States public dataset, TCIA.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K231855 FDA decision evidence for QOCA® image Smart RT Contouring System

  • DesignFDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation.
  • PopulationAdult patient anatomy represented in CT images and radiation-treatment structures
  • Scopeexact submission
  • Tested versionQOCA image Smart RT Contouring System, model ZSWR901
  • IndependenceSponsor or vendor study

K231855

The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K231855 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or contouring value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CT or MR images, structures, patient identity, treatment-planning data, and user selections.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K231855: QOCA® image Smart RT Contouring System

  2. Routing

    Source context, not route validation: The FDA indication describes DICOM CT input, RTSTRUCT output, and a web-based interface for settings, user settings, progress, and other functions; validate DICOM RT structure transfer, patient identity, review, acceptance, and rollback locally.

    Scope: Exact FDA submission. The exact FDA material describes this input or interface boundary; local interoperability acceptance remains necessary.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K231855: QOCA® image Smart RT Contouring System

  3. AI processing

    Source context, not route validation: The FDA indication describes a web-based management interface but does not establish hosting, security, availability, retention, or site responsibility for the exact release.

    Scope: Exact FDA submission. The exact FDA material describes this release-level deployment boundary; hosting, contracts, security, availability, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K231855: QOCA® image Smart RT Contouring System

  4. Returned objects

    Source context, not route validation: Contours, RTSTRUCT objects, plans, dose or evaluation results, or review information requiring qualified acceptance.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K231855: QOCA® image Smart RT Contouring System

  5. Viewer/worklist/report

    Unresolved route: Contours, RTSTRUCT objects, plans, dose or evaluation results, or review information requiring qualified acceptance.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K231855: QOCA® image Smart RT Contouring System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA indication describes a web-based management interface but does not establish hosting, security, availability, retention, or site responsibility for the exact release.
  • Exact FDA submission
  • Checked 2026-09-04

The exact FDA material describes this release-level deployment boundary; hosting, contracts, security, availability, and site configuration remain separate evidence.

Integration
The FDA indication describes DICOM CT input, RTSTRUCT output, and a web-based interface for settings, user settings, progress, and other functions; validate DICOM RT structure transfer, patient identity, review, acceptance, and rollback locally.
  • Exact FDA submission
  • Checked 2026-09-04

The exact FDA material describes this input or interface boundary; local interoperability acceptance remains necessary.

Training
Only qualified radiation oncologists, medical physicists, dosimetrists, radiation therapists, and trained planning staff should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication limits valid input to adult-patient DICOM images, states that the software does not automatically detect or contour lesions, and requires appropriate treatment-planning or interactive-contouring software to review, edit, and accept the contours.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K231855 before acceptance. Later family features are not evidence for this exact submission.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA indication describes DICOM CT input, RTSTRUCT output, and a web-based interface for settings, user settings, progress, and other functions; validate DICOM RT structure transfer, patient identity, review, acceptance, and rollback locally. Test representative identifiers, geometry, measurements, units, routing, failure handling, and round trips locally.

exact submission · checked 2026-09-04

Deployment and security qualification

The FDA indication describes a web-based management interface but does not establish hosting, security, availability, retention, or site responsibility for the exact release. Security, availability, retention, and service responsibilities remain unverified.

exact submission · checked 2026-09-04

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA indication limits valid input to adult-patient DICOM images, states that the software does not automatically detect or contour lesions, and requires appropriate treatment-planning or interactive-contouring software to review, edit, and accept the contours.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication limits valid input to adult-patient DICOM images, states that the software does not automatically detect or contour lesions, and requires appropriate treatment-planning or interactive-contouring software to review, edit, and accept the contours.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231855
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Adult patient anatomy represented in CT images and radiation-treatment structures
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-02-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
33Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K231855: QOCA® image Smart RT Contouring System

    U.S. Food and Drug Administration - Published 2024-02-13 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

Research history

  1. K231855 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252190

DeepBT Detector-Plus

Aitewan Biomedical Technology, Inc.

Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
Decision
2026-04-10
FDA-cleared K252304

syngo.via RT Image Suite VC10

Varian Medical Systems, Inc.

Authorized purpose: syngo.via RT Image Suite VC10 provides three-dimensional and four-dimensional multimodality visualization, registration, fusion, contouring, and planning support for radiation-treatment preparation.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain, pelvis, thorax, abdomen, targets, organs at risk, and moving tumors or organs
Decision
2026-03-18
FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K250427

TAIMedImg DeepMets

Taiwan Medical Imaging Co., Ltd.

Authorized purpose: TAIMedImg DeepMets assists trained professionals by providing initial gross-tumor-volume contours on axial contrast-enhanced T1 brain MR images for radiation-treatment planning in adults with known brain metastases; the contours require thorough review and are not a replacement for manual contouring.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain metastases in adults
Decision
2025-05-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history